SUSTAINED 2-YEAR REMISSION OF THE DISEASE IN A CLINIC OF EXCELLENCE IN RHEUMATOID ARTHRITIS. EXPERIENCE OF THE CLINICAL REGISTRY IN COLOMBIA

被引：0
作者：
Bello-Gualtero, J. M. [1 ,2 ]
Pena, E. [3 ]
Moreno, P. I. Santos [4 ]
Gualdron, J. Vesga [3 ]
Saavedra, G. [5 ]
Perez, C. [6 ]
机构：
[1] Hosp Mil Cent, Rheumatol & Immunol, Bogota, Colombia
[2] Univ Mil Nueva Granada, Grp Inmunol Clin Aplicada, Bogota, Colombia
[3] Pontificia Univ Javeriana, Hlth Econ, Bogota, Colombia
[4] BIOMAB IPS, Rheumatol, Bogota, Colombia
[5] Hosp Mil Cent, Epidemiol, Bogota, Colombia
[6] Hosp Mil Cent, Cuenta Alto Costo, Bogota, Colombia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.3886
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0501
引用
收藏
页码：483 / 483
页数：1
相关论文
共 50 条
  • [41] INITIAL INFLIXIMAB IS NOT COST-EFFECTIVE IN OTHERWISE ACTIVELY TREATED EARLY RHEUMATOID ARTHRITIS. THE 2-YEAR FOLLOW-UP RESULTS OF THE RANDOMIZED CLINICAL NEO-RACO TRIAL
    Rantalaiho, V.
    Martikainen, J.
    Kautiainen, H.
    Puolakka, K.
    Leirisalo-Repo, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 85 - 85
  • [42] MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
    Hetland, M. L.
    Ejbjerg, B.
    Horslev-Petersen, K.
    Jacobsen, S.
    Vestergaard, A.
    Jurik, A. G.
    Stengaard-Pedersen, K.
    Junker, P.
    Lottenburger, T.
    Hansen, I.
    Andersen, L. S.
    Tarp, U.
    Skjodt, H.
    Pedersen, J. K.
    Majgaard, O.
    Svendsen, A. J.
    Ellingsen, T.
    Lindegaard, H.
    Christensen, A. F.
    Vallo, J.
    Torfing, T.
    Narvestad, E.
    Thomsen, H. S.
    Ostergaard, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (03) : 384 - 390
  • [43] Bimekizumab-treated patients with active psoriatic arthritis showed sustained achievement of minimal disease activity and remission: Up to 2-year results from two phase 3 studies
    Coates, L. C.
    Kristensen, L. E.
    Ogdie, A.
    Tillett, W.
    Ink, B.
    Goldammer, N.
    Bajracharya, R.
    Coarse, J.
    Orbai, A. M.
    SWISS MEDICAL WEEKLY, 2024, 154 : 35S - 35S
  • [44] SUSTAINED LONG-TERM EFFICACY OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A 2-YEAR ANALYSIS OF THE RAPID 1 STUDY
    Smolen, Josef
    Keystone, Ed
    Schiff, Michael
    Mease, Philip
    van Vollenhoven, Ronald
    Desai, Chintu
    RHEUMATOLOGY, 2009, 48 : I85 - I86
  • [45] Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
    Coates, Laura C.
    Nash, Peter
    Kvien, Tore K.
    Gossec, Laure
    Mease, Philip J.
    Rasouliyan, Lawrence
    Pricop, Luminita
    Jugl, Steffen M.
    Gandhi, Kunal K.
    Gaillez, Corine
    Smolen, Josef S.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) : 709 - 718
  • [46] LONG TERM EFFICACY OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON DISEASE ACTIVITY, MRI INFLAMMATION AND PHYSICAL FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION: FIVE YEAR FOLLOW-UP OF THE IMAGINE RA-COHORT
    Moller-Bisgaard, S.
    Horslev-Petersen, K.
    Glinatsi, D.
    Ejbjerg, B.
    Hetland, M. L.
    Moller, J. Mollenbach
    Christensen, R.
    Nielsen, S. M.
    Boesen, M.
    Stengaard-Pedersen, K.
    Madsen, O.
    Jensen, B.
    Villadsen, J. A.
    Hauge, E. M.
    Hendricks, O.
    Lindegaard, H. M.
    Krogh, N. Steen
    Jurik, A. G.
    Thomsen, H.
    Ostergaard, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 539 - 540
  • [47] Initial infliximab is not cost-effective added on to a remission-targeted combination therapy in early rheumatoid arthritis: the 2-year results of the randomized clinical NEO-RACo trial
    Rantalaiho, V.
    Martikainen, J.
    Kautiainen, H.
    Puolakka, K.
    Leirisalo-Repo, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 1 - 1
  • [48] Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
    Coates, Laura C.
    Gladman, Dafna D.
    Nash, Peter
    FitzGerald, Oliver
    Kavanaugh, Arthur
    Rasouliyan, Lawrence
    Pricop, Luminita
    Ding, Kevin
    Gaillez, Corine
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [49] Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease: 2-year clinical experience
    Zhang, Shulan
    Luo, Jing
    Li, Ji
    Wu, Ziyan
    Hu, Chaojun
    Li, Ping
    Deng, Chuiwen
    Zhang, Fengchun
    Qian, Jiaming
    Li, Yongzhe
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (06) : 865 - 875
  • [50] Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial
    Moller-Bisgaard, Signe
    Horslev-Petersen, Kim
    Ornbjerg, Lykke Midtboll
    Ejbjerg, Bo
    Hetland, Merete Lund
    Moller, Jakob Mollenbach
    Nielsen, Sabrina Mai
    Glinatsi, Daniel
    Boesen, Mikael
    Stengaard-Pedersen, Kristian
    Madsen, Ole Rintek
    Jensen, Bente
    Villadsen, Jan Alexander
    Hauge, Ellen Margrethe
    Hendricks, Oliver
    Lindegaard, Hanne
    Krogh, Niels Steen
    Jurik, Anne Grethe
    Thomsen, Henrik
    Christensen, Robin
    Ostergaard, Mikkel
    RMD OPEN, 2024, 10 (01):
12345